当前对膀胱癌最有前途的蛋白质组学和糖组学生物标志物的研究。

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.

机构信息

Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia.

出版信息

J Cancer Res Clin Oncol. 2024 Feb 19;150(2):96. doi: 10.1007/s00432-024-05623-7.

DOI:10.1007/s00432-024-05623-7

PMID:38372785

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10876723/

Abstract

BACKGROUND

Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential.

METHODS

We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%.

FINDINGS

Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC.

摘要

背景

膀胱癌（BC）属于最常见的癌症类型之一。其诊断过程仍然漫长且昂贵，存在高比例的假阳性或假阴性结果。由于成本和效果不佳，需要用更新、更可靠的方法来补充或替代旧的方法。在这方面，蛋白质和糖蛋白具有很大的潜力。

方法

我们在 PubMed/Medline、Scopus 和 Web of Science 数据库中进行了在线检索，以查找截至 2023 年 5 月以英文发表的相关研究。如果适用，我们将 AUC 阈值设置为 0.90，灵敏度/特异性（SN/SP）设置为 90%。

结果

蛋白质和糖蛋白生物标志物在 BC 诊断中具有明显的可行性。胆碱酯酶在无进展生存期方面显示出一定的潜力。BLCA-4、ORM-1 和 HTRA1 可用于检测 BC。基质金属蛋白酶 9 具有分层肌浸润亚型的潜力，对侵袭性表型具有较高的阴性预测值。区分非肌浸润亚型可受益于角蛋白 17。Neu5Gc 修饰的 UMOD 糖蛋白在 BC 诊断中有一定的应用潜力，而纤连蛋白、层粘连蛋白-5、IV 型胶原和七鳃鳗免疫蛋白则可用于 BC 的早期检测。